Volume 27, Issue 4 - Patient-reported outcomes

My First Medical Writing

Authors: Evguenia Alechine, Matías Rey-Carrizo

Abstract

Download the full article

References

1. FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018 [cited 2018 Sep 19]. Available from Available from: https://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm611046.htm.
2. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: an example of taxonomic neglect. Bot Mus Lealf Harv Univ. 1974;23:337–67.
3. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76(1-2):3–8.
4. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;105(1-2):1–25.
5. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153–7.
6. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc. 1964;86(8):1646–7.
7. Devane WA, Dysarz FA, Johnson RM, Melvin S, Howlett C. Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol Pharmacol. 1988;34(5):605–13.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
9. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science. 1992;258(10):1946–9.
10. Elder JJ, Knoderer HM. Characterization of Dronabinol Usage in a Pediatric Oncology Population. J Pediatr Pharmacol Ther. 2015;20(6):462–7.
11. Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467–77.
12. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(8).
13. Syed YY, McKeage K, Scott LJ. Delta-9- Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs. 2014;74(5):563–78.
14. Kalant H. Medical use of cannabis: History and current status. Pain Res Manage. 2011;6(2):80–91.
15. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A Random ized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. J Pain. 2008;9(6):506–21.
16. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmaco - therapy. 2013;33(2):195–209.17.
17. Scuderi C, De Filipis D, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders. Phytother Res. 2009;23:597–602.
18. Devinsky O, Cross JH, FRCPCH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–20.
19. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.
20. Rosemergy I, Adler J, Psirides A. Cannabidiol oil in the treatment of super refractory status epilepticus. A case report. Seizure. 2016;35:56–8.
21. Shannon S, Opila-Lehman J. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integr Med. 2015;14(6):31–5.
22. Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224–7.
23. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016;20(4):108–11.